Journal of Thoracic Oncology 2022 April 27 [Link] Amber Louw, Vasiliki Panou, Weronika Maria Szejniuk, Christos Meristoudis, Siaw Ming Chai, Chris van Vliet, Y C Gary Lee, Ian M Dick, Tina Firth, Louise Andersen Lynggaard, Azadeh Birbaneh Asghari, Mogens Vyberg, Johnni Hansen, Jenette Creaney, Oluf Dimitri Røe Abstract Introduction: Pleural mesothelioma (PM) is an aggressive…

Read More

Histopathology 2022 April 23 [Link] William J Anderson, Lynette M Sholl, Christopher D M Fletcher, Stephanie Schulte, Li Juan Wang, Fiona M Maclean, Michelle S Hirsch Abstract Aims: Malignant mesothelioma (MM) of the tunica vaginalis (TV) is a rare and aggressive tumor, and the molecular features and staining profile with contemporary immunohistochemical (IHC) biomarkers are…

Read More

Cancer Diagnosis and Prognosis 2021 July 3 [Link] Shajedul Islam, Takao Kitagawa, Yasuhiro Kuramitsu Abstract Background/aim: Malignant pleural mesothelioma (MPM) is a rare but very aggressive tumor that is primarily pleural in origin. The 5-year overall survival rate of patients with MPM has not improved despite therapeutic advances. Therefore, biomarker discovery to identify premalignant or…

Read More

Frontiers in Cell and Development Biology 2022 March 22 [Link] Luca Hegedüs, Kata D Szücs, Matthias Kudla, Julian Heidenreich, Verena Jendrossek, Samuel Peña-Llopis, Tamas Garay, Andras Czirok, Clemens Aigner, Till Plönes, Silvia Vega-Rubin-de-Celis, Balazs Hegedüs Abstract Malignant pleural mesothelioma (MPM) is a rare type of cancer with a grim prognosis. So far, no targetable oncogenic…

Read More

Lung 2022 April 8 [Link] Koki Nakashima, Yasuhiro Sakai, Hitomi Hoshino, Yukihiro Umeda, Hiroto Kawashima, Yoshitaka Sekido, Tamotsu Ishizuka, Motohiro Kobayashi Abstract Purpose: Malignant pleural mesothelioma (MPM) is a malignant neoplasm of the pleura caused by asbestos exposure. For diagnosis of MPM, immunohistochemistry using multiple markers is recommended to rule out differential diagnoses, such as…

Read More

Lung Cancer 2022 March 2 [Link] Alexander Davis, Helen Ke, Steven Kao, Nick Pavlakis Abstract The treatment paradigm for malignant pleural mesothelioma (MPM) has changed little in the last 18 years. Radical intent treatment, consisting of surgical resection, radiotherapy and chemotherapy, has been offered to a highly select few; however, there is little randomised evidence…

Read More

BMC Cancer 2022 February 20 [Link] Martina Vivoda Tomšič, Peter Korošec, Viljem Kovač, Sotirios Bisdas, Katarina Šurlan Popovič Abstract Background: The malignant pleural mesothelioma (MPM) response rate to chemotherapy is low. The identification of imaging biomarkers that could help guide the most effective therapy approach for individual patients is highly desirable. Our aim was to…

Read More

Analytical Chemistry 2022 February 8 [Link] Oana M Voloaca, Malcolm R Clench, Gunda Koellensperger, Laura M Cole, Sarah L Haywood-Small, Sarah Theiner Abstract This is the first report of the use of laser ablation-inductively coupled plasma time-of-flight mass spectrometry (LA-ICP-TOFMS) to analyze human malignant pleural mesothelioma (MPM) samples at the cellular level. MPM is an…

Read More

Biochemical Genetics 2022 January 20 [Link] Qi Zhang, Zhiqiang Wang, Huarong Cai, Dongming Guo, Wei Xu, Shi Bu, Yuequan Jiang Abstract The deregulation of circular RNAs (circRNAs) is involved in cancer development. CircRNA polo-like kinase 1 (circPLK1) was reported to promote breast cancer development. However, the role of circPLK1 in malignant pleural mesothelioma (MPM) is…

Read More

PeerJ 2022 January 4 [Link] Yun Gao, Ziyi Dai, Chenxi Yang, Ding Wang, Zhenying Guo, Weimin Mao, Zhongjian Chen Abstract Background: Malignant mesothelioma (MM) is a rare and highly aggressive cancer. Despite advances in multidisciplinary treatments for cancer, the prognosis for MM remains poor with no effective diagnostic biomarkers currently available. The aim of this…

Read More